KALA BIO's Agent Goes Live
KALA BIO launched its Bionic Intelligence Research Agent — a secure, scalable, agentic AI platform now live for biotech customers to run autonomous research workflows. The release signals agentic AI moving from pilot projects into regulated, production research environments. (globenewswire.com)
BIRA runs on Researgent 2.0, a 70‑billion‑parameter large language model Kala says was trained on biotech, healthcare and scientific research datasets. (markets.financialcontent.com) KALA secured an exclusive worldwide license to the Researgency platform from Younet under a March 3, 2026 agreement that calls for issuing 5,000,000 shares of common stock and up to $530,000 in cash during the initial 12‑month term, with each renewal triggering an additional $250,000 and 5,000,000 shares and an irrevocable option to acquire Younet for $55,000,000. (sec.gov) Kala describes the product as an on‑premises, client‑controlled deployment that runs in VPN‑only environments and provides complete audit trails plus pre‑built connectors to scientific literature, clinical trial, regulatory and patent databases. (markets.financialcontent.com) The company told investors on March 4 that it will first apply Researgency to its own MSC‑S biological datasets and the KPI‑012 clinical program before offering the platform to external biotech customers. (markets.businessinsider.com) Kala announced a 14‑day shipping commitment on March 11 and CEO Avi Minkowitz said the company met that timeline in the March 30 disclosure. (markets.businessinsider.com) (markets.financialcontent.com) An early commercial engagement reported by Kala places Red Light Holland as a client using Researgency to support clinical development of Filament’s patented PEX010 botanical psilocybin candidate. (markets.businessinsider.com) Kala’s disclosed near‑term agent roadmap lists event alerts, continuous patent/IP monitoring and compressed publication‑review capabilities as features it plans to roll out for biotech R&D users. (stocktitan.net)
